Usfda Approval
-
{
- All
- News
- Videos
-
Alembic Pharma Gets US Drug Regulator's Nod For Anti-Migraine Drug
The tablets are indicated for acute treatment of migraine in adults.
-
Strides Shasun R&D Unit Gets US Health Regulator's Closure Report
Shares of Strides Shasun were trading at Rs 1,077 apiece, up 0.13 per cent, from its previous close on the BSE
-
US Food Regulator Made 9 Observations Post Halol Unit Inspection: Sun Pharma
Sun Pharma was earlier issued a warning letter by the USFDA for its Halol facility in December 2015.
-
Lupin Gets US Regulator's Nod For Hypertension Treatment Drug In US
Olmesartan Medoximil tablets, a generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Zydus Cadila Gets USFDA Nod For Diabetes Treatment Drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Nateglinide tablets tablets USP, in the strengths of 60 mg and 120 mg, Zydus Cadila's group firm Cadila Healthcare said in a BSE filing.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Sensex, Nifty Recover On Likely Tax Relief For FPIs
Here’s a quick look at all that could influence equities today.
-
Zydus Cadila Gets U.S. FDA Nod To Market Acne Drug
Clindamycin is an antibiotic that stops the growth of acne-causing bacteria.
-
This Mobile Brain Scanner Promises to Assess Injuries Where CT Scans Can’t
BrainScope One uses a disposable electrode headpiece and machine learning software.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Wockhardt Gets U.S. Health Regulator’s Approval For Generic Eye Drops
Wockhardt gets final approval from the U.S. FDA for generic version of Novartis eye drops.
-
Aurobindo Pharma Stock Rallies On Kidney Disease Drug Approval
This will be the 116th abbreviated new drug application approval for Aurobindo Pharma.
-
Sun Pharma Shares Rise On Approval For Anti-Cholesterol Drug
Ezetimibe had annual sales of $2.7 billion in the U.S. in the 12 months ended April.
-
Cadila Gets U.S. Regulator’s Nod For Antidepressant Pills
Zydus Cadila gets approval to market an anti depressant in the U.S. market.
-
Alembic Pharma Gets US Drug Regulator's Nod For Anti-Migraine Drug
The tablets are indicated for acute treatment of migraine in adults.
-
Strides Shasun R&D Unit Gets US Health Regulator's Closure Report
Shares of Strides Shasun were trading at Rs 1,077 apiece, up 0.13 per cent, from its previous close on the BSE
-
US Food Regulator Made 9 Observations Post Halol Unit Inspection: Sun Pharma
Sun Pharma was earlier issued a warning letter by the USFDA for its Halol facility in December 2015.
-
Lupin Gets US Regulator's Nod For Hypertension Treatment Drug In US
Olmesartan Medoximil tablets, a generic version of Daiichi Sankyo's Benicar, are indicated for the treatment of hypertension, along with other anti-hypertensive agents to lower blood pressure, it added.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Zydus Cadila Gets USFDA Nod For Diabetes Treatment Drug
Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Nateglinide tablets tablets USP, in the strengths of 60 mg and 120 mg, Zydus Cadila's group firm Cadila Healthcare said in a BSE filing.
-
Zydus Cadila's US Firm Gets US Approval To Market Roflumilast Tablets
Cadlia Healthcare Ltd on Monday said group firm Zydus Pharmaceuticals (USA) Inc has received final approval from the US health regulator to market its generic version of Roflumilast tablets in the strength of 500 mcg indicated to reduce the risk of
-
Sensex, Nifty Recover On Likely Tax Relief For FPIs
Here’s a quick look at all that could influence equities today.
-
Zydus Cadila Gets U.S. FDA Nod To Market Acne Drug
Clindamycin is an antibiotic that stops the growth of acne-causing bacteria.
-
This Mobile Brain Scanner Promises to Assess Injuries Where CT Scans Can’t
BrainScope One uses a disposable electrode headpiece and machine learning software.
-
Zydus Cadila's Anti-Diabetic Drug Gets USFDA Marketing Nod
The company has received tentative approval to market sitagliptin and metformin hydrochloride.
-
Wockhardt Gets U.S. Health Regulator’s Approval For Generic Eye Drops
Wockhardt gets final approval from the U.S. FDA for generic version of Novartis eye drops.
-
Aurobindo Pharma Stock Rallies On Kidney Disease Drug Approval
This will be the 116th abbreviated new drug application approval for Aurobindo Pharma.
-
Sun Pharma Shares Rise On Approval For Anti-Cholesterol Drug
Ezetimibe had annual sales of $2.7 billion in the U.S. in the 12 months ended April.
-
Cadila Gets U.S. Regulator’s Nod For Antidepressant Pills
Zydus Cadila gets approval to market an anti depressant in the U.S. market.
